Q3 EPS Forecast for Eyepoint Pharmaceuticals Cut by Analyst

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Eyepoint Pharmaceuticals in a report released on Tuesday, October 20th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.85) for the quarter, down from their prior estimate of ($0.60). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.51) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ FY2026 earnings at ($3.40) EPS and Q3 2027 earnings at $0.45 EPS.

Several other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price on the stock. Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating for the company in a research note on Tuesday. Jefferies Financial Group cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a report on Monday. Mizuho restated a “neutral” rating and issued a $0.50 price target on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Finally, Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Stock Up 6.1%

Shares of EYPT stock opened at $0.43 on Thursday. The company has a 50 day moving average price of $4.25 and a 200-day moving average price of $10.12. Eyepoint Pharmaceuticals has a 52 week low of $0.39 and a 52 week high of $19.11. The firm has a market capitalization of $37.07 million, a PE ratio of -0.11 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth $29,000. Integrated Wealth Concepts LLC bought a new position in Eyepoint Pharmaceuticals in the 2nd quarter worth $72,000. Pictet Asset Management Holding SA bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth $141,000. Engineers Gate Manager LP purchased a new position in Eyepoint Pharmaceuticals during the second quarter valued at $161,000. Finally, Janney Montgomery Scott LLC lifted its position in Eyepoint Pharmaceuticals by 14.8% during the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after purchasing an additional 3,900 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Traders purchased a large volume of EYPT call options, signaling increased speculative interest and expectations that the stock could rebound or move sharply higher. Stock Traders Purchase Large Volume of Call Options on Eyepoint Pharmaceuticals
• Positive Sentiment: RBC identified the company’s upcoming diabetic macular edema (DME) study readout as a potential catalyst. Positive data could help offset the recent failure of an EyePoint wet age-related macular degeneration (wAMD) trial to meet its endpoint. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint
• Neutral Sentiment: Analyst sentiment remains mixed across EyePoint and other healthcare companies, reflecting uncertainty over the company’s clinical pipeline and future catalysts. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Laidlaw reaffirmed its “hold” rating. RBC also maintained a “sector perform” view while cutting its price target to $1.00, and Mizuho reaffirmed “neutral” with a $0.50 target. These targets remain above the recent share price but indicate limited conviction.
• Negative Sentiment: Jefferies Financial Group lowered its rating on EyePoint, adding to pressure from a more cautious analyst outlook. Eyepoint Pharmaceuticals Stock Rating Lowered by Jefferies
• Negative Sentiment: Guggenheim also downgraded the stock, reinforcing concerns after the wAMD trial miss and highlighting the high-risk nature of EyePoint’s development program. Eyepoint Pharmaceuticals Stock Gets Downgrade from Guggenheim

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.